Advanced Proteome Therapeutics Stock Number Of Shares Shorted
APTCF Stock | USD 0.0002 0.00 0.00% |
Advanced Proteome Therapeutics fundamentals help investors to digest information that contributes to Advanced Proteome's financial success or failures. It also enables traders to predict the movement of Advanced Pink Sheet. The fundamental analysis module provides a way to measure Advanced Proteome's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Advanced Proteome pink sheet.
Advanced |
Advanced Proteome Therapeutics Company Number Of Shares Shorted Analysis
Advanced Proteome's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Competition |
Based on the recorded statements, Advanced Proteome Therapeutics has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 100.0% higher than that of the company.
Advanced Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Advanced Proteome's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Advanced Proteome could also be used in its relative valuation, which is a method of valuing Advanced Proteome by comparing valuation metrics of similar companies.Advanced Proteome is currently under evaluation in number of shares shorted category among its peers.
Advanced Fundamentals
Return On Asset | -1.07 | |||
Current Valuation | 660.53 K | |||
Shares Outstanding | 41.13 M | |||
Shares Owned By Insiders | 10.53 % | |||
Price To Earning | 2.98 X | |||
Price To Book | 4.92 X | |||
Gross Profit | (1.71 K) | |||
EBITDA | 631.22 K | |||
Net Income | 759.62 K | |||
Cash And Equivalents | 761.6 K | |||
Cash Per Share | 0.02 X | |||
Total Debt | 227.41 K | |||
Debt To Equity | 4.65 % | |||
Current Ratio | 0.55 X | |||
Book Value Per Share | 0.01 X | |||
Cash Flow From Operations | (693.58 K) | |||
Earnings Per Share | 0.02 X | |||
Number Of Employees | 11 | |||
Beta | 1.55 | |||
Market Capitalization | 2.47 M | |||
Total Asset | 636.41 K | |||
Z Score | 6.0 | |||
Net Asset | 636.41 K |
About Advanced Proteome Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Advanced Proteome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Advanced Proteome using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Advanced Proteome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Advanced Pink Sheet
Advanced Proteome financial ratios help investors to determine whether Advanced Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Advanced with respect to the benefits of owning Advanced Proteome security.